An Analysis of Potential Surrogate Markers of Target-Specific Therapy in Archival Materials of Adrenocortical Carcinoma

被引:21
作者
Nakamura, Megumi [2 ,3 ]
Miki, Yasuhiro [2 ]
Akahira, Jun-ichi [2 ]
Morimoto, Ryo [4 ]
Satoh, Fumitoshi [4 ]
Ishidoya, Shigeto [5 ]
Arai, Yoichi [5 ]
Suzuki, Takashi [6 ]
Hayashi, Yutaka [3 ]
Sasano, Hironobu [1 ,2 ]
机构
[1] Tohoku Univ, Sch Med, Dept Pathol, Aoba Ku, Sendai, Miyagi 9808574, Japan
[2] Tohoku Univ, Grad Sch Med, Dept Pathol, Aoba Ku, Sendai, Miyagi 9808574, Japan
[3] Tohoku Univ, Grad Sch Med, Dept Pediat Surg, Aoba Ku, Sendai, Miyagi 9808574, Japan
[4] Tohoku Univ, Grad Sch Med, Dept Internal Med, Div Nephrol Endocrinol & Vasc Med,Aoba Ku, Sendai, Miyagi 9808574, Japan
[5] Tohoku Univ, Grad Sch Med, Dept Urol, Aoba Ku, Sendai, Miyagi 9808574, Japan
[6] Tohoku Univ, Sch Hlth Sci, Dept Pathol, Aoba Ku, Sendai, Miyagi 9808574, Japan
关键词
adrenocortical carcinoma; target-specific therapy; EGFR; Ras/ERK pathway; PI3K/Akt pathway; immunohistochemistry; ENDOTHELIAL GROWTH-FACTOR; TRANSLATION INITIATION; SIGNALING NETWORK; CANCER; KINASE; MTOR; ACTIVATION; EXPRESSION; MUTATIONS; PATHWAYS;
D O I
10.1007/s12022-009-9058-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Adrenocortical carcinoma (ACC) is a rare neoplasm but some of the cases are highly malignant. Clinical outcome of the patients with advanced ACC still remained poor or dismal despite recent development of aggressive antitumor therapies. Target-specific therapies have been developed in a number of human malignancies and resulted in therapeutic benefits in some cancer patients. However, these therapies are only effective in the cases in which corresponding targets are expressed in tumor tissues. Therefore, we evaluated expression of potential surrogate markers using immunohistochemistry in archival materials of adrenocortical carcinoma in order to explore the potential application of target specific therapies in ACC in this study. We immunolocalized ten established or potential surrogate markers of target-specific therapies, located in the Ras/extracellular signal-regulated kinase and phosphatidylinositol-3 kinase/Akt pathways, in 41 ACC cases, 54 adrenocortical adenoma (ACA) cases, and five nonpathological adrenal glands and correlated the findings with clinicopathological factors of the patients. Among these markers examined, only epidermal growth factor receptor (EGFR) was significantly more abundant in ACC than in ACA (P < 0.01). These findings suggest that the agents which specifically inhibit signal transductions through EGFR such as monoclonal antibodies against EGFR are considered to be worthwhile to be attempted in future clinical studies.
引用
收藏
页码:17 / 23
页数:7
相关论文
共 37 条
[1]   Key cancer cell signal transduction pathways as therapeutic targets [J].
Bianco, RB ;
Melisi, D ;
Ciardiello, F ;
Tortora, G .
EUROPEAN JOURNAL OF CANCER, 2006, 42 (03) :290-294
[2]   Advances in protein kinase B signalling:: AKTion on multiple fronts [J].
Brazil, DP ;
Yang, ZZ ;
Hemmings, BA .
TRENDS IN BIOCHEMICAL SCIENCES, 2004, 29 (05) :233-242
[3]   PDK-1/AKT pathway as a novel therapeutic target in rhabdomyosarcoma cells using OSU-03012 compound [J].
Cen, L. ;
Hsieh, F-C ;
Lin, H-J ;
Chen, C-S ;
Qualman, S. J. ;
Lin, J. .
BRITISH JOURNAL OF CANCER, 2007, 97 (06) :785-791
[4]   Protocol modifications influence the result of EGF receptor immunodetection by EGFR pharmDX™ in paraffin-embedded cancer tissues [J].
Derecskei, Katalin ;
Moldvay, Judit ;
Bogos, Krisztina ;
Timar, Jozsef .
PATHOLOGY & ONCOLOGY RESEARCH, 2006, 12 (04) :243-246
[5]   A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas [J].
Duran, I. ;
Kortmansky, J. ;
Singh, D. ;
Hirte, H. ;
Kocha, W. ;
Goss, G. ;
Le, L. ;
Oza, A. ;
Nicklee, T. ;
Ho, J. ;
Birle, D. ;
Pond, G. R. ;
Arboine, D. ;
Dancey, J. ;
Aviel-Ronen, S. ;
Tsao, M-S ;
Hedley, D. ;
Siu, L. L. .
BRITISH JOURNAL OF CANCER, 2006, 95 (09) :1148-1154
[6]   The biology of VEGF and its receptors [J].
Ferrara, N ;
Gerber, HP ;
LeCouter, J .
NATURE MEDICINE, 2003, 9 (06) :669-676
[7]   Regulation of translation initiation by FRAP/mTOR [J].
Gingras, AC ;
Raught, B ;
Sonenberg, N .
GENES & DEVELOPMENT, 2001, 15 (07) :807-826
[8]   Clinical significance of angiogenic factor expression at the deepest invasive site of advanced colorectal carcinoma [J].
Kaio, E ;
Tanaka, S ;
Kitadai, Y ;
Sumii, M ;
Yoshihara, M ;
Haruma, K ;
Chayama, K .
ONCOLOGY, 2003, 64 (01) :61-73
[9]   Levels of mTOR and its downstream targets 4E-BP1, eEF2, and eEF2 kinase in relationships with tau in Alzheimer's disease brain [J].
Li, X ;
Alafuzoff, I ;
Soininen, H ;
Winblad, B ;
Pei, JJ .
FEBS JOURNAL, 2005, 272 (16) :4211-4220
[10]  
Lin F, 2006, ANN CLIN LAB SCI, V36, P283